Nature research paper: PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program
This work was supported by National Institutes of Health grants R01AI030048 , P01AI056299 , P50CA101942 , P01CA236749 , R01AI129191 , P50CA217691 , and the Roche pRED ROADS programme .
Masao Hashimoto, Koichi Araki, Haydn T. Kissick, William H. Hudson, Donald J. McGuire, Rebecca C. Obeng, Andreas Wieland, Judong Lee, Daniel T. McManus, James L. Ross, Se Jin Im, Junghwa Lee & Rafi AhmedMasao Hashimoto, Koichi Araki, Haydn T. Kissick, William H. Hudson, Donald J. McGuire, Rebecca C. Obeng, Andreas Wieland, Judong Lee, Daniel T. McManus, James L. Ross, Se Jin Im, Junghwa Lee, Christopher D.
Division of Infectious Diseases, Center for Inflammation and Tolerance, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USADepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USAMaria A. Cardenas & Haydn T. Kissick Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute , National Institutes of Health , Bethesda, MD, USADepartment of Immunology, Mayo Clinic School of Medicine and Sciences, Rochester, MN, USADepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, USAWinship Cancer Institute, Emory University, Atlanta, GA, USADepartment of Pathology, Emory University School of Medicine, Atlanta,...
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Injecting Modified Herpes Virus Shows Promise Of Killing Off Cancer CellsA genetically modified version of the herpes virus that causes cold sores has shown promise in killing off cancer cells in early stage clinical trials, with one patient experiencing a complete remission of 15 months so far. What do you think?
Les mer »
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape - Nature MedicineA new dual-chimeric antigen receptor (CAR) system enhances the antitumor activity of CAR natural killer cells and makes them less susceptible to therapeutic resistance in preclinical models. lab_rezvani CARNK therapyresistance
Les mer »
CRISPR screens in Drosophila cells identify Vsg as a Tc toxin receptor - NatureA genome-wide CRISPR–Cas9-mediated knockout screen in Drosophila cells identifies Visgun as a proteinaceous receptor for toxin complex toxins, demonstrating the utility of this approach for investigating insecticidal toxins and pathogens.
Les mer »
Visualizing translation dynamics at atomic detail inside a bacterial cell - NatureCryo-electron tomography is used to reveal the structural dynamics and functional diversity of translating ribosomes in Mycoplasma pneumoniae, providing insight into the translation elongation cycle inside cells and how it is reshaped by antibiotics.
Les mer »
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma - Nature MedicineAnalysis of outcomes of over 800 patients with relapsed/refractory diffuse large B cell lymphoma, treated with commercially available CAR T cell therapy, supports higher efficacy and also a higher toxicity of axicabtagene ciloleucel compared to tisagenlecleucel as the third or more treatment line for this type of tumor.
Les mer »